{"id":10612,"date":"2022-07-29T12:00:00","date_gmt":"2022-07-29T12:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3830976_CN30976_0"},"modified":"2022-07-29T12:00:00","modified_gmt":"2022-07-29T12:00:00","slug":"hanall-biopharma-reports-second-quarter-2022-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=10612","title":{"rendered":"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update"},"content":{"rendered":"<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1806733\/logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Financial performance for Q2 2022 records revenues of <span class=\"xn-money\">KRW 26.2 billion<\/span>, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division &nbsp;<\/li>\n<li>Operating income turned to profit compared to the last quarter, while investment to R&amp;D continued in the second quarter<\/li>\n<li>Immunovant initiated Phase 3 clinical study in MG and HanAll completed a meeting with PMDA to initiate a Phase 3 study in MG in <span class=\"xn-location\">Japan<\/span> in 2H 2022<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 29, 2022<\/span><\/span> \/PRNewswire\/ &#8212; HanAll Biopharma (KRX: 009420.KS), a global biopharmaceutical company focusing on delivering breakthrough therapies for patients, reported financial results for the second quarter 2022 as well as an update to its R&amp;D progress.<\/p>\n<p>&#8220;The second quarter delivered strong momentum for HanAll Biopharma. Our operating income has turned to profit while we continued our investment in R&amp;D&#8221; said <span class=\"xn-person\">Sean Jeong<\/span>, M.D., CEO of HanAll Biopharma.<\/p>\n<p>&#8220;Moving forward over the next few quarters, we expect to see topline results for the Phase 3 study in dry eye disease in the US, while enhancing our portfolio through open collaborations. HanAll will continue to invest in R&amp;D to bring innovative therapeutics to patients&#8221; he added.<\/p>\n<p><b>SECOND QUARTER 2022 BUSINESS UPDATE <br \/><\/b><b>Pipeline Development Highlights &nbsp;<\/b><\/p>\n<p>A comprehensive update on HanAll&#8217;s pipeline development includes an overview of HanAll&#8217;s research and a list of compounds in development with targeted indication and the phase of development.<\/p>\n<p><b>Batoclimab (Project Code: HL161)<\/b><\/p>\n<p><i>A novel, fully human, anti-FcRn antibody being developed as a subcutaneous injection for the treatment of rare autoimmune diseases mediated by pathogenic IgG antibodies. <\/i><\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">March 2022<\/span>, Harbour BioMed, a licensed partner of HanAll updated full clinical development progress in batoclimab. The company is progressing towards Biologics License Application (BLA) submission in the calendar year of 2022, after obtaining topline results from Phase 3 clinical trial for myasthenia gravis (MG). Harbour is developing batoclimab in a wide range of autoimmune indications in addition to MG, including immune thrombocytopenic purpura (ITP), neuromyelitis optica spectrum disorder (NMOSD) and thyroid eye disease (TED).<\/li>\n<li>In <span class=\"xn-chron\">June 2022<\/span>, Immunovant, a global licensed partner of HanAll initiated a Phase 3 study to further evaluate the efficacy of batoclimab in MG. Immunovant expects to reveal two new indication programs by <span class=\"xn-chron\">August 2022<\/span>.<\/li>\n<li>HanAll Biopharma plans to initiate a Phase 3 clinical trial in MG in collaboration with Immunovant in <span class=\"xn-location\">Japan<\/span>, during the 2H 2022.&nbsp;<\/li>\n<\/ul>\n<p><b>Tanfanercept (Project Code: HL036)<\/b><\/p>\n<p><i>A novel, topical anti-TNF alpha biologic therapy for dry eye disease (DED) which aims to treat inflammatory eye diseases by inhibiting TNF alpha, which is critical in ocular inflammation.<\/i><\/p>\n<ul type=\"disc\">\n<li>HanAll Biopharma and Daewoong Pharmaceutical are continuing to conduct their second Phase 3 clinical study (Study name: VELOS-3) in DED to examine the safety and efficacy of the medication, at nine clinical sites located in the U.S. <span id=\"spanHghlt8065\">The study design was recently expanded to include a pharmacogenomics component that could deliver more value for patients and prescribers from this study.&nbsp;<\/span><\/li>\n<li>Harbour BioMed is conducting its pivotal Phase 3 trial on tanfanercept in patients with DED.<\/li>\n<\/ul>\n<p><b>HL187\/ HL186<\/b><\/p>\n<p><i>HanAll is advancing its development in immuno-oncology therapeutics, that respectively target TIM-3 and TIGIT with Daewoong Pharmaceutical.<\/i><\/p>\n<ul type=\"disc\">\n<li>HL187 is in pre-clinical development and antibody screening is ongoing to select the lead molecule in HL186.<\/li>\n<\/ul>\n<p><b>Major Development Highlights <\/b><\/p>\n<p>HanAll further advanced its partnerships with companies with promising technologies.&nbsp;<\/p>\n<ul type=\"disc\">\n<li>HanAll supported Neudive, a company developing digital therapeutic solutions to help neurodiverse children. Neudive&#8217;s platform is expected to deliver individually tailored therapy programs to children with neurodevelopmental disorders by using VR technology.<\/li>\n<\/ul>\n<p><b>FINANCIAL HIGHLIGHTS <\/b><b>(PROVISIONAL)<br \/><\/b><b>Key Highlights<\/b><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"0\" class=\"prnbcc\">\n<tbody readability=\"3.5\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">(KRW in millions)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q2 2022<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q2 2021<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">% change<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Sales<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>26,250<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>23,437<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>12.0&nbsp;%<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Gross Profit<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">14,941<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">13,708<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">9.0&nbsp;%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prnpr2 prnpl2 prnvab prnsbtb1 prnbrbrs prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Selling, marketing and administrative expenses<br \/><\/span><\/p>\n<\/td>\n<td class=\"prngen9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10,567<\/span><\/p>\n<\/td>\n<td class=\"prngen9\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">9,591<\/span><\/p>\n<\/td>\n<td class=\"prnpr2 prnpl2 prnvab prntac prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">10.2&nbsp;%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"3\">\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Research and development expenses<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">3,692<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">2,545<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">45.1&nbsp;%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"3\">\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Operating income \/ (loss)<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">682<\/span><\/p>\n<\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,572<\/span><\/p>\n<\/td>\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">-56.6&nbsp;%<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<ul type=\"disc\">\n<li><b>Sales<\/b>&nbsp;were <span class=\"xn-money\">26.2 billion won<\/span> in the second quarter, a 12% increase compared to the same period last year. Sales growth was mainly driven by continued strong performance from pharmaceuticals sold under the names of Normix, Eligard, Biotop and other major products.<\/li>\n<li><b>R&amp;D expenses<\/b>&nbsp;showed 45.1 % increase compared to the same period last year, recording around <span class=\"xn-money\">3.6 billion won<\/span>.<\/li>\n<li><b>Operating income<\/b>&nbsp;was <span class=\"xn-money\">682 million won<\/span>, a 56.6% decrease, compared to the same period last year, mainly due to increased investment in R&amp;D.<\/li>\n<\/ul>\n<p><b>About HanAll Biopharma Co., Ltd.&nbsp;<\/b><\/p>\n<p>HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company founded in 1973, with a mission of making meaningful contributions to patients&#8217; lives by introducing innovative, impactful therapies to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for more than 48 years.&nbsp;<\/p>\n<p>HanAll has also expanded its focus to ophthalmology, immunology, oncology and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. A leading pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody drug, is in Phase 3 and Phase 2 trials across the world for the treatment of rare autoimmune disorders including myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, and immune thrombocytopenia. Another main asset, HL036 (INN: tanfanercept), an anti-TNF alpha protein drug, is in Phase 3 clinical trials in the US and <span class=\"xn-location\">China<\/span> for the treatment of dry eye disease.&nbsp;<\/p>\n<p>For further information visit our <u><a href=\"http:\/\/www.hanall.com\/\" target=\"_blank\" rel=\"nofollow noopener\">website<\/a><\/u>, and connect with us on <u><a href=\"https:\/\/www.linkedin.com\/company\/hanall\" target=\"_blank\" rel=\"nofollow noopener\">linkedin<\/a><\/u>. For any media inquiries, please contact HanAll PR\/IR <u>(<a href=\"mailto:pr@hanall.com\" target=\"_blank\" rel=\"nofollow noopener\">pr@hanall.com<\/a><\/u>, <u><a href=\"mailto:ir@hanall.com\" target=\"_blank\" rel=\"nofollow noopener\">ir@hanall.com<\/a><\/u>).&nbsp;&nbsp;<\/p>\n<p><b>Disclaimer statement<\/b><\/p>\n<p><i>The contents of this announcement include statements that are, or may be deemed to be, &#8220;forward-looking statements.&#8221; These forward-looking statements can be identified by the use of forward-looking terminology, including the terms &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or &#8220;should&#8221; and include statements HANALL (the company, we) makes concerning its 2022 business and financial<\/i>&nbsp;<i>outlook and related plans, the therapeutic potential of its product candidates, the intended results of its strategy and the company, and its collaboration partners&#8217;, advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts, the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company&#8217;s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors our expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements, our reliance on collaborations with third parties, estimating the commercial potential of our product candidates, our ability to obtain and maintain protection of intellectual property for its technologies and drugs, our limited operating history, and our ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in Korea Stock Exchange (KRX) filings and reports, including in our most recent annual report as well as subsequent filings and reports filed by the company with the KRX. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. We undertake no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by Korean law and regulations.<\/i>&nbsp;<\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN30976&amp;sd=2022-07-29\"> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/hanall-biopharma-reports-second-quarter-2022-results-and-provides-business-update-301596014.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/hanall-biopharma-reports-second-quarter-2022-results-and-provides-business-update-301596014.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division &nbsp; Operating income turned to profit compared to the last quarter, while investment to R&amp;D continued in the second quarter Immunovant initiated Phase 3 clinical study [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-10612","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=10612\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update - My Blog\" \/>\n<meta property=\"og:description\" content=\"Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division &nbsp; Operating income turned to profit compared to the last quarter, while investment to R&amp;D continued in the second quarter Immunovant initiated Phase 3 clinical study [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=10612\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-29T12:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1806733\/logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update\",\"datePublished\":\"2022-07-29T12:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612\"},\"wordCount\":1252,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1806733\\\/logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612\",\"name\":\"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1806733\\\/logo.jpg?p=medium600\",\"datePublished\":\"2022-07-29T12:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1806733\\\/logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1806733\\\/logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=10612#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=10612","og_locale":"en_US","og_type":"article","og_title":"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update - My Blog","og_description":"Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division &nbsp; Operating income turned to profit compared to the last quarter, while investment to R&amp;D continued in the second quarter Immunovant initiated Phase 3 clinical study [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=10612","og_site_name":"My Blog","article_published_time":"2022-07-29T12:00:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1806733\/logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=10612#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=10612"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update","datePublished":"2022-07-29T12:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=10612"},"wordCount":1252,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=10612#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1806733\/logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=10612","url":"https:\/\/transmediavictoria.net.au\/?p=10612","name":"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=10612#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=10612#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1806733\/logo.jpg?p=medium600","datePublished":"2022-07-29T12:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=10612#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=10612"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=10612#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/1806733\/logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/1806733\/logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=10612#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/10612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10612"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/10612\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}